Discussion
MCI, Alzheimer’s Disease, dementia, cognitive impairment
The COMCID phase 2 randomized clinical trial found that cilostazol was safe but did not improve cognition. A dose-dependent decrease in the incidence of dementia due to cilostazol treatment was reported in a nationwide cohort study in TaiwanRegrettably, cilostazol did not yield significant improvements in cognitive function. This outcome may be attributable to the possibility that the participants in the present study were in advanced stages of MCI, particularly late MCI. This becomes particularly apparent when comparing the baseline characteristics of the patients with MCI in our study (mean age, 75.6 [5.2] years; mean [SD] baseline MMSE scores, 25.5 [1.9] and mean [SD] baseline CDR-SB scores, 2.6 [1.0]) with those enrolled in the Japanese Alzheimer’s Disease Neuroimaging Initiative study, one of Japan’s largest cohort studies, who were younger and had scores indicating milder cognitive impairment (mean [SD] age, 72.5 [5.8] years; mean [SD] baseline MMSE scores, 26.6 [1.8] and mean [SD] baseline CDR-SB scores, 1.6 [0.9]).Another study by some of us,